2-(2-(2-fluoroethoxy)ethoxy)ethyl 4-methylbenzenesulfonate | 1071476-71-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-(2-fluoroethoxy)ethoxy)ethyl 4-methylbenzenesulfonate
• 英文别名: 2-[2-(2-fluoroethoxy)ethoxy]ethyl 4-methylbenzene-1-sulfonate；2-[2-(2-fluoroethoxy)ethoxy]ethyl 4-methylbenzenesulfonate
• CAS: 1071476-71-5
• 化学式: C₁₃H₁₉FO₅S
• 分子量: 306.355
• InChiKey: MHUIIHOKCRBQES-UHFFFAOYSA-N

物化性质

• 沸点：
  425.7±35.0 °C(Predicted)
• 密度：
  1.203±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  20
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  70.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(2-(2-fluoroethoxy)ethoxy)ethyl 4-methylbenzenesulfonate 在 copper(l) iodide 、 sodium azide 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-4-(1-(2-(2-(2-fluoroethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-benzamide
  参考文献：
  名称：

  Synthesis and Structure–Activity Relationship Studies of Conformationally Flexible Tetrahydroisoquinolinyl Triazole Carboxamide and Triazole Substituted Benzamide Analogues as σ₂ Receptor Ligands

  摘要：

  Two novel classes of compounds targeting the sigma-2 (sigma(2)) receptor were synthesized, and their bioactivities to binding sigma(1) and sigma(2) receptors were measured. Four novel triazole carboxamide analogues, 24d, 24e, 24f, and 39c, demonstrated high affinity and selectivity for the sigma(2) receptor. These data suggest C-11-labeled versions of these compounds may be potential sigma(2)-selective radiotracers for imaging the proliferative status of solid tumors.

  DOI：

  10.1021/jm5001453
• 作为产物：
  描述：

  对甲苯磺酰氯 在 四丁基氟化铵 、 potassium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 2-(2-(2-fluoroethoxy)ethoxy)ethyl 4-methylbenzenesulfonate
  参考文献：
  名称：

  新型18 F标记的2-吡啶基苯并恶唑和2-吡啶基苯并噻唑衍生物作为配体的β-淀粉样蛋白正电子发射断层显像（PET）的合成和评价

  摘要：

  合成了一系列氟代聚乙二醇化（FPEG）2-吡啶基苯并恶唑和2-吡啶基苯并噻唑衍生物，并将其作为PET的新型β-淀粉样（Aβ）成像探针进行了评估。他们表现出对Aβ1–42聚集体的结合亲和力，范围从2.7到101.6 nM。选择了七个具有高亲和力的配体进行18 F标记。体外放射自显影结果证实了这些放射性示踪剂的高亲和力。在正常小鼠中进行的体内生物分布实验表明，具有短FPEG链（n = 1）的放射性示踪剂显示出较高的初始摄入量并迅速从大脑中清除。2-吡啶基苯并恶唑衍生物之一，[ 18 F] -5-（5-（2-氟乙氧基）苯并[ d ]恶唑-2-基）-N-甲基吡啶-2-胺（[ 18 F] 32）（K i = 8.0±3.2 nM）的大脑2min /大脑60min之比为4.66，这对于Aβ显像剂而言是非常理想的。[ 18 F] 32与Aβ斑块的靶标特异性结合通过转基因模型小鼠的体外放射自显影实验得到验证。总体而言，[

  DOI：

  10.1021/jm300973k

文献信息

• [EN] NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION<br/>[FR] NOUVEAUX AGENTS D'IMAGERIE POUR LA DÉTECTION D'UNE DYSFONCTION NEUROLOGIQUE
  申请人：SIEMENS MEDICAL SOLUTIONS

  公开号：WO2009102498A1

  公开（公告）日：2009-08-20

  Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease

  本文披露了一种在哺乳动物中诊断阿尔茨海默病或其易感性的化合物和方法，该方法包括向哺乳动物投与一种放射标记化合物的诊断有效量，所述化合物选自放射标记黄酮类、香豆素类、咔唑类、喹诺酮类、色酮类、咪唑类和三唑类衍生物组成的群体，使化合物分布到脑组织中，并对脑组织进行成像，其中与正常控制水平的结合相比，化合物对脑组织的结合增加表明哺乳动物患有或有发展阿尔茨海默病的风险
• [EN] CARBAZOLE AND CARBOLINE COMPOUNDS FOR USE IN THE DIAGNOSIS, TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH AMYLOID OR AMYOLID-LIKE PROTEINS<br/>[FR] COMPOSÉS DE CARBAZOLE ET DE CARBOLINE DESTINÉS À ÊTRE UTILISÉS DANS LE DIAGNOSTIC, LE TRAITEMENT, L'ATTÉNUATION OU LA PRÉVENTION DE TROUBLES ASSOCIÉS AUX PROTÉINES AMYLOÏDES ET DE TYPE AMYLOÏDE
  申请人：AC IMMUNE SA

  公开号：WO2015110263A1

  公开（公告）日：2015-07-30

  The present invention relates to novel compounds that can be employed in the diagnosis, treatment, alleviation or prevention of a group of disorders and abnormalities associated with amyloid proteins and amyloid-like proteins, such as Alzheimer's disease. Precursors for the preparation of the compounds according to the present invention are also provided.

  本发明涉及一种新型化合物，可用于诊断、治疗、缓解或预防与淀粉样蛋白和类淀粉样蛋白相关的一组疾病和异常，如阿尔茨海默病。本发明还提供了制备这些化合物的前体。
• Carbazole and Carboline Compounds for Use in the Diagnosis, Treatment, Alleviation or Prevention of Disorders Associated with Amyloid or Amyloid-Like Proteins
  申请人：AC IMMUNE SA

  公开号：US20170002005A1

  公开（公告）日：2017-01-05

  The present invention relates to novel compounds that can be employed in the diagnosis, treatment, alleviation or prevention of a group of disorders and abnormalities associated with amyloid proteins and amyloid-like proteins, such as Alzheimer's disease. Precursors for the preparation of the compounds according to the present invention are also provided.

  本发明涉及可用于诊断、治疗、缓解或预防与淀粉样蛋白和类淀粉样蛋白相关的一组疾病和异常的新化合物，如阿尔茨海默病。本发明还提供了制备这些化合物的前体。
• [EN] SELECTIVE LIGANDS FOR TAU AGGREGATES<br/>[FR] LIGANDS SÉLECTIFS POUR AGRÉGATS TAU
  申请人：KARIN & STEN MORTSTEDT CBD SOLUTIONS AB

  公开号：WO2019197502A1

  公开（公告）日：2019-10-17

  The invention provides a compound of formula (I): or a pharmaceutically acceptable salt, ester, amide or carbamate thereof, or a salt of such an ester, amide or carbamate.The invention further provides uses of the compounds of formula (I) and compositions comprising compounds of formula (I), including the use of such compounds for the detection of tau deposits, and the use of such compounds and compositions as diagnostic agents in the diagnosis or monitoring of the progression of a disease or disorder such as Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy,or for the prevention or treatment of a disease or disorder such as Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy.

  该发明提供了化合物的结构式(I)：或其药学上可接受的盐、酯、酰胺或碳酸酯，或此类酯、酰胺或碳酸酯的盐。该发明还提供了化合物的结构式(I)的用途和包括化合物的结构式(I)的组合物，包括利用这些化合物检测tau沉积物的用途，以及将这些化合物和组合物用作诊断剂在诊断或监测疾病或障碍的进展，如阿尔茨海默病、皮质基底节变性和进行性上核性麻痹症，或用于预防或治疗疾病或障碍，如阿尔茨海默病、皮质基底节变性和进行性上核性麻痹症。
• Imaging agents for detecting neurological disorders
  申请人：Gangadharmath Umesh B.

  公开号：US20100239496A1

  公开（公告）日：2010-09-23

  Imaging agents of formula (I) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formula (I) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formula (I) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.

  本文提供了一种公式（I）的成像剂和检测神经系统疾病的方法，包括向需要的患者施用能够结合tau蛋白和β-淀粉样肽的公式（I）化合物。该发明还涉及成像Aβ和tau聚集物的方法，包括引入含有公式（I）放射标记化合物的制剂的可检测量，并检测与淀粉样沉积物和/或tau蛋白相关的标记化合物在患者体内的情况。这些方法和组合物使得能够进行临床前诊断和监测阿尔茨海默病和其他神经系统疾病的进展。